Table 1 Baseline characteristics
Population (n = 187) | SARS-CoV-2 negative (n = 52) | SARS-CoV-2 positive (n = 135) | |
|---|---|---|---|
Teaching hospital | 137 (73.3) | 40 (76.9) | 97 (71.9) |
Patients origin | |||
Emergency department | 39 (23.0) | 16 (35.6) | 23 (17.6) |
Surgical ward | 24 (14.1) | 3 (6.7) | 21 (16.8) |
Medical ward | 49 (28.8) | 13 (28.9) | 36 (28.8) |
Intensive care unit | 37 (21.8) | 4 (8.9) | 33 (26.4) |
Transfer | 21 (12.4) | 9 (20.0) | 12 (9.6) |
Age (years) | 65 [54; 76] | 69 [55; 77] | 64 [53; 76] |
Gender, male | 118 (63.4) | 30 (57.7) | 88 (65.7) |
Delay first symptoms—anesthesia | 12 [4; 27] | 3 [2; 9] | 17 [8; 31] |
Delay first symptoms – anesthesia | |||
First week | 49 (33.1) | 26 (66.7) | 23 (21.1) |
Second week | 29 (19.6) | 7 (17.9) | 22 (20.2) |
Third week | 25 (16.9) | 1 (2.6) | 24 (22.0) |
Fourth week | 8 (5.4) | 0 (0.0) | 8 (7.3) |
Fith week and more | 37 (25.0) | 5 (12.8) | 32 (29.4) |
Respiratory symptoms | 83 (44.9) | 13 (25.5) | 70 (52.2) |
Surgical specialty | |||
Visceral | 45 (25.7) | 19 (36.5) | 29 (21.5) |
Orthopedic | 41 (21.9) | 6 (11.5) | 35 (25.9) |
Urology | 18 (9.6) | 7 (13.5) | 11 (8.1) |
Vascular | 20 (10.7) | 9 (17.3) | 11 (8.1) |
Gastro Intestinal endoscopy | 16 (8.6) | 6 (11.5) | 10 (7.4) |
Neurosurgery | 19 (10.2) | 3 (5.8) | 16 (11.9) |
Other | 25 (13.3) | 2 (3.8) | 23 (17.0) |
Emergency surgery | 163 (87.6) | 47 (90.4) | 116 (86.6) |
Surgical delay for emergency patients, min | 360 [177; 1380] | 240 [121; 720] | 360 [180; 1440] |
Surgery Risk Stratification | |||
Very low risk | 15 (8.0) | 5 (9.6) | 10 (7.4) |
Low risk | 38 (20.3) | 8 (15.7) | 30 (22.2) |
Intermediate risk | 98 (52.4) | 25 (48.1) | 73 (54.1) |
High risk | 31 (16.6) | 12 (23.1) | 19 (14.1) |
Very high risk | 5 (2.7) | 2 (3.8) | 3 (2.2) |
ARISCAT Score | 49 [36; 67] | 40 [27; 48] | 56 [41; 68] |
ARISCAT Risk Group, % | |||
Low | 17 (9.1) | 11 (21.2) | 6 (4.4) |
Intermediate | 63 (33.7) | 22 (42.3) | 41 (30.4) |
High | 107 (57.2) | 19 (30.5) | 88 (65.2) |
Active smoking | 27 (14.5) | 11 (21.2) | 16 (11.9) |
ASA-PS | |||
1 | 16 (8.6) | 4 (7.7) | 12 (9.0) |
2 | 56 (30.1) | 15 (28.8) | 41 (30.6) |
3 | 81 (43.5) | 26 (50.0) | 55 (41.0) |
4 | 33 (17.4) | 7 (13.5) | 26 (19.4) |
High Blood pressure | 93 (50.3) | 24 (46.2) | 69 (51.9) |
BMI, kg.m–2 | 25.6 [23; 29] | 25 [22; 29] | 26 [23; 29] |
BMI > = 30 | 39 (22.3) | 11 (22.9) | 28 (22.0) |
Current treatment | |||
Immunosuppressors | 14 (7.5) | 2 (3.8) | 12 (9.0) |
Steroids | 22 (11.8) | 4 (7.7) | 18 (13.4) |
Antihypertensives | 50 (27.0) | 14 (26.9) | 36 (27.1) |
Oral antidiabetics | 23 (12.4) | 5 (9.6) | 18 (13.4) |
NSAIDS | 8 (4.3) | 4 (7.7) | 4 (3.0) |
Insulin | 28 (15.1) | 4 (7.7) | 24 (18.0) |
Radiotherapy or chemotherapy | 11 (7.1) | 3 (7.0) | 8 (7.1) |
SOFA Score | 2 [0; 5] | 2 [1; 5] | 2 [0; 5] |
Creatinine, mmol/L | 80 [59; 120] | 87 [65; 123] | 79 [56; 115] |
Hemoglobin, g/dL | 11.4 [9.6; 13.3] | 12.6 [10.9; 13.9] | 11.0 [8.7; 13.0] |
White blood cell count, × 109/L | 10,5 [7.0; 15.2] | 12.3 [7.9; 17.9] | 10.0 [6.8; 14.3] |
Lymphocyte count, × 109/L | 1.0 [0.7; 1.6] | 1.0 [0.8; 1.8] | 1.1 [0.7; 1.4] |
Preoperative SpO2, % | 97 [95; 99] | 96 [95; 99] | 97 [95; 99] |
SpO2/FiO2 ratio | 440 [250; 462] | 448 [345; 462] | 419 [213; 462] |
Preoperative oxygen support | |||
No oxygen | 100 (54.3) | 33 (64.7) | 67 (50.4) |
Oxygen ≥ 1L.min−1 | 47 (25.5) | 14 (27.5) | 33 (24.8) |
Mechanical ventilation | 37 (20.1) | 4 (7.8) | 33 (24.8) |